[
  {
    "ts": "2026-02-19T05:14:30+00:00",
    "headline": "PTC Inc. (PTC) Faces Price Target Cuts, But Analysts See Stability",
    "summary": "PTC Inc. (NASDAQ:PTC) is among the most profitable software stocks to buy now. On February 9, TheFly reported that BofA reduced its price target on PTC Inc. (NASDAQ:PTC) to $172, down from $190, and reiterated a Neutral rating. The company’s macroeconomic backdrop remains challenging but shows no further deterioration, the firm noted. That said, it […]",
    "url": "https://finance.yahoo.com/news/ptc-inc-ptc-faces-price-051430604.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "97ed9f38-8559-3800-a013-de909b83ff3c",
      "content": {
        "id": "97ed9f38-8559-3800-a013-de909b83ff3c",
        "contentType": "STORY",
        "title": "PTC Inc. (PTC) Faces Price Target Cuts, But Analysts See Stability",
        "description": "",
        "summary": "PTC Inc. (NASDAQ:PTC) is among the most profitable software stocks to buy now. On February 9, TheFly reported that BofA reduced its price target on PTC Inc. (NASDAQ:PTC) to $172, down from $190, and reiterated a Neutral rating. The company’s macroeconomic backdrop remains challenging but shows no further deterioration, the firm noted. That said, it […]",
        "pubDate": "2026-02-19T05:14:30Z",
        "displayTime": "2026-02-19T05:14:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/25057720e13ffcfeddfe5ee3eaf6e0df",
          "originalWidth": 852,
          "originalHeight": 562,
          "caption": "AppLovin (APP) PT Lowered to $686 by UBS Following Strong Q4 2025 Performance, Axon 2.0 Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vEgJVUTJErrga4oDCdm2Ug--~B/aD01NjI7dz04NTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/25057720e13ffcfeddfe5ee3eaf6e0df.cf.webp",
              "width": 852,
              "height": 562,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7QYFQOSjKlNyH_9Yo1QIKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/25057720e13ffcfeddfe5ee3eaf6e0df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ptc-inc-ptc-faces-price-051430604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ptc-inc-ptc-faces-price-051430604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T22:18:35+00:00",
    "headline": "PTC Therapeutics stock down over 2% on worse-than-expected Q4 results, guidance",
    "summary": "Investing.com -- PTC Therapeutics (NASDAQ: PTCT) reported fourth-quarter results that missed Wall Street expectations on both earnings and revenue, even as management pointed to strong momentum from the recent launch of Sephience™. Shares fell 2.7% following the update. For the fourth quarter of 2025, PTC posted a net loss of $135.0 million, or ($1.67) per diluted share, compared with a loss of ($0.85) per share a year earlier. The result was well below the consensus estimate of ($0.26). Total r",
    "url": "https://finance.yahoo.com/news/ptc-therapeutics-stock-down-over-221835089.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "87222b72-3fba-3a90-95c2-f27a7b2148f0",
      "content": {
        "id": "87222b72-3fba-3a90-95c2-f27a7b2148f0",
        "contentType": "STORY",
        "title": "PTC Therapeutics stock down over 2% on worse-than-expected Q4 results, guidance",
        "description": "",
        "summary": "Investing.com -- PTC Therapeutics (NASDAQ: PTCT) reported fourth-quarter results that missed Wall Street expectations on both earnings and revenue, even as management pointed to strong momentum from the recent launch of Sephience™. Shares fell 2.7% following the update. For the fourth quarter of 2025, PTC posted a net loss of $135.0 million, or ($1.67) per diluted share, compared with a loss of ($0.85) per share a year earlier. The result was well below the consensus estimate of ($0.26). Total r",
        "pubDate": "2026-02-19T22:18:35Z",
        "displayTime": "2026-02-19T22:18:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ptc-therapeutics-stock-down-over-221835089.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ptc-therapeutics-stock-down-over-221835089.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PTCT"
            },
            {
              "symbol": "PTC"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]